Manzari, Mandana T. http://orcid.org/0000-0002-1163-9649
Shamay, Yosi
Kiguchi, Hiroto http://orcid.org/0000-0003-0180-8813
Rosen, Neal
Scaltriti, Maurizio http://orcid.org/0000-0002-5522-1447
Heller, Daniel A. http://orcid.org/0000-0002-6866-0000
Article History
Accepted: 24 November 2020
First Online: 2 February 2021
Competing interests
: D.A.H. is a co-founder and officer with equity interest in Goldilocks Therapeutics, Inc., LipidSense, Inc. and Nirova BioSense, Inc., as well as a member of the scientific advisory boards of Concarlo Holdings, LLC and Nanorobotics, Inc. M.S. is a full-time employee at AstraZeneca, has received research funds from Puma Biotechnology, AstraZeneca, Daiichi Sankyo, Immunomedics, Targimmune and Menarini Ricerche, is a co-founder of Medendi.org and is on the advisory board of Menarini Ricerche. N.R. is on the scientific advisory board (SAB) of Chugai, BeiGene, Fortress Biotech, Daiichi Sankyo, AstraZeneca, F-Prime, Zai Lab, Arvinas and Array BioPharma, and is a past SAB member of Millennium Takeda, Kadmon, Kura Oncology and Araxes. N.R. is also a consultant to Novartis Biomedical, Boehringer Ingelheim, Tarveda, Foresite Capital, Array BioPharma and Revolution Medicines, and, in recent years, has also consulted with Eli Lilly, Merrimack, Kura Oncology, Araxes and Kadmon. N.R. owns equity in BeiGene, Zai Lab, Fortress Biotech, Kura Oncology, Araxes, Kadmon and Effector. N.R. is a full-time employee at National Resilience Inc., collaborates with Plexxikon and receives research support from Chugai.